$2.16
0.92% today
Nasdaq, Feb 05, 08:48 pm CET
ISIN
US46333X1081
Symbol
IRWD

Ironwood Pharmaceuticals Stock price

$2.18
-2.32 51.56% 1M
-4.02 64.84% 6M
-2.25 50.79% YTD
-12.57 85.22% 1Y
-8.87 80.27% 3Y
-10.42 82.70% 5Y
-10.51 82.81% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.09 4.06%
ISIN
US46333X1081
Symbol
IRWD
Sector
Industry

Key metrics

Market capitalization $348.86m
Enterprise Value $875.52m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 7.07
EV/Sales (TTM) EV/Sales 2.31
P/S ratio (TTM) P/S ratio 0.92
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -12.48%
Revenue (TTM) Revenue $378.42m
EBIT (operating result TTM) EBIT $117.06m
Free Cash Flow (TTM) Free Cash Flow $123.82m
Cash position $88.21m
EPS (TTM) EPS $-0.02
P/E forward 28.07
P/S forward 0.98
EV/Sales forward 2.47
Short interest 11.41%
Show more

Is Ironwood Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Ironwood Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Ironwood Pharmaceuticals forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Ironwood Pharmaceuticals forecast:

Buy
83%
Hold
17%

Financial data from Ironwood Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
378 378
12% 12%
100%
- Direct Costs 2.04 2.04
46% 46%
1%
376 376
13% 13%
99%
- Selling and Administrative Expenses 138 138
4% 4%
36%
- Research and Development Expense 120 120
34% 34%
32%
119 119
40% 40%
31%
- Depreciation and Amortization 2.04 2.04
46% 46%
1%
EBIT (Operating Income) EBIT 117 117
41% 41%
31%
Net Profit -2.46 -2.46
100% 100%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about Ironwood Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ironwood Pharmaceuticals Stock News

Neutral
Business Wire
7 days ago
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced a streamlined strategic focus on advancing and realizing the potential of apraglutide for the treatment of short bowel syndrome (“SBS”) patients who are dependent on ...
Negative
CNBC
19 days ago
The Biden administration unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare. It kicks off the second phase of a landmark provision in the Inflation Reduction Act that aims to make costly medications more affordable for seniors.
Neutral
Business Wire
2 months ago
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET at the Lotte New York Palace. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.i...
More Ironwood Pharmaceuticals News

Company Profile

Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.

Head office United States
CEO Thomas McCourt
Employees 267
Founded 1998
Website www.ironwoodpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today